Precision medicine: the foundation of future cancer therapeutics

This publication has 41 references indexed in Scilit:

• One-Step Generation of Mice Carrying Mutations in Multiple Genes by CRISPR/Cas-Mediated Genome Engineering
  Cell, 2013
• A framework for human microbiome research
  Nature, 2012
• Phase II, Open-Label, Randomized, Multicenter Study Comparing the Efficacy and Safety of Olaparib, a Poly (ADP-Ribose) Polymerase Inhibitor, and Pegylated Liposomal Doxorubicin in Patients With BRCA1 or BRCA2 Mutations and Recurrent Ovarian Cancer
  Journal of Clinical Oncology, 2012
• Targeting MYC dependence in cancer by inhibiting BET bromodomains
  Proceedings of the National Academy of Sciences, 2011
• BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
  Cell, 2011
• RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
  Nature, 2011
• Harnessing synthetic lethal interactions in anticancer drug discovery
  Nature Reviews Drug Discovery, 2011
• Cancer: an old disease, a new disease or something in between?
  Nature Reviews Cancer, 2010
• Therapeutic potential of a synthetic lethal interaction between the MYC proto-oncogene and inhibition of aurora-B kinase
  Proceedings of the National Academy of Sciences, 2010
• The Concept of Synthetic Lethality in the Context of Anticancer Therapy
  Nature Reviews Cancer, 2005